Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    2,759

Stocks News & Analysis

stocks

OpenAI is going public as the worst value among its peers

Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks

Wide moat healthcare leader remains undervalued

ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks

This US AI winner has been unstoppable. Is it time to sell?

Astonishing results have driven this AI stock into significantly overvalued territory.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,855.9079.60-0.89%
CAC 408,218.2426.05-0.32%
DAX 4024,759.05185.90-0.75%
Dow JONES (US)50,866.78695.15-1.35%
FTSE 10010,368.057.730.07%
HKSE24,961.95291.45-1.15%
NASDAQ25,709.431,121.53-4.18%
Nikkei 22566,588.12882.57-1.31%
NZX 50 Index13,161.9760.360.46%
S&P 5007,383.74200.57-2.64%
S&P/ASX 2008,625.1080.00-0.92%
SSE Composite Index4,027.7430.04-0.74%

Market Movers